300267.SZ Stock Analysis
30
Avoid
Based on Eyestock quantitative analysis, 300267.SZ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Hunan Er-Kang Pharmaceutical Co., Ltd. engages in the research and development, production and sale of pharmaceutical products. The company is headquartered in Changsha, Hunan and currently employs 1,612 full-time employees. The company went IPO on 2011-09-27. The Company’s pharmaceutical excipients mainly consist of glycerol for medicine, sugar for medicine, ethanol for medicine, propylene glycol for medicine, as well as sodium hydroxide for medicine and others. Its bulk drugs consist of sulfadiazine, sulphaguanidine and resorcinol, among others. Its finished drugs consist of sulbenicillin sodium injections and compound liquorice tablets. The firm distributes its products in domestic market and to overseas markets.